These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19052557)

  • 1. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
    Bruennert D; Czibere A; Bruns I; Kronenwett R; Gattermann N; Haas R; Neumann F
    Leukemia; 2009 May; 23(5):983-5. PubMed ID: 19052557
    [No Abstract]   [Full Text] [Related]  

  • 2. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
    Neumann F; Teutsch N; Kliszewski S; Bork S; Steidl U; Brors B; Schimkus N; Roes N; Germing U; Hildebrandt B; Royer-Pokora B; Eils R; Gattermann N; Haas R; Kronenwett R
    Leukemia; 2005 Mar; 19(3):458-60. PubMed ID: 15618956
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
    Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.
    Mustjoki S; Rohon P; Rapakko K; Jalkanen S; Koskenvesa P; Lundán T; Porkka K
    Leukemia; 2010 Jan; 24(1):219-22. PubMed ID: 19776759
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
    Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
    Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
    Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
    J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY; Tse E; So JC; Wan TS; Kwong YL
    Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic myelogenous leukemia. Preface.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):ix-x. PubMed ID: 22054737
    [No Abstract]   [Full Text] [Related]  

  • 11. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A; Al Bahar S; Ramesh P
    Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
    J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract]   [Full Text] [Related]  

  • 14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J
    Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 17. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.